Literature DB >> 21403841

A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.

Kee Ming Chia1, Ji Liu, Glenn D Francis, Ali Naderi.   

Abstract

Estrogen receptor (ER)-negative breast cancer is heterogeneous, and the biology of this disease has remained poorly understood. Molecular apocrine is a subtype of ER-negative breast cancer that is characterized by the overexpression of steroid-response genes such as AR and a high rate of ErbB2 amplification. In this study, we have identified a positive feedback loop between the AR and extracellular signal-regulated kinase (ERK) signaling pathways in molecular apocrine breast cancer. In this process, AR regulates ERK phosphorylation and kinase activity. In addition, AR inhibition results in the down-regulation of ERK target proteins phospho-RSK1, phospho-Elk-1, and c-Fos using an in vivo molecular apocrine model. Furthermore, we show that AR-mediated induction of ERK requires ErbB2, and AR activity, in turn, regulates ErbB2 expression as an AR target gene. These findings suggest that ErbB2 is an upstream connector between the AR and ERK signaling pathways. Another feature of this feedback loop is an ERK-mediated regulation of AR. In this respect, the inhibition of ERK phosphorylation reduces AR expression and CREB1-mediated transcriptional regulation of AR acts as a downstream connector between the AR and ERK signaling pathways in molecular apocrine cells. Finally, we demonstrate that AR-positive staining is associated with the overexpression of ERK signaling targets phospho-Elk-1 and c-Fos in ER-negative breast tumors, which further supports a cross-regulation between the AR and ERK signaling pathways in molecular apocrine subtype. This study demonstrates an AR-ERK feedback loop in ER-negative breast cancer with significant biologic and therapeutic implications in this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403841      PMCID: PMC3033594          DOI: 10.1593/neo.101324

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  37 in total

Review 1.  Function and regulation of CREB family transcription factors in the nervous system.

Authors:  Bonnie E Lonze; David D Ginty
Journal:  Neuron       Date:  2002-08-15       Impact factor: 17.173

2.  Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase.

Authors:  J Xing; D D Ginty; M E Greenberg
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

3.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  Activation of the c-fos enhancer by the erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites.

Authors:  Y Wang; R Prywes
Journal:  Oncogene       Date:  2000-03-09       Impact factor: 9.867

Review 5.  Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction.

Authors:  M Frödin; S Gammeltoft
Journal:  Mol Cell Endocrinol       Date:  1999-05-25       Impact factor: 4.102

6.  Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis.

Authors:  Thomas C Putti; Dalia M Abd El-Rehim; Emad A Rakha; Claire E Paish; Andrew H S Lee; Sarah E Pinder; Ian O Ellis
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

7.  BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer.

Authors:  Ali Naderi; Ji Liu; Luke Hughes-Davies
Journal:  Mol Cancer       Date:  2010-05-19       Impact factor: 27.401

8.  Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.

Authors:  Guillaume Banneau; Mickaël Guedj; Gaëtan MacGrogan; Isabelle de Mascarel; Valerie Velasco; Renaud Schiappa; Valerie Bonadona; Albert David; Catherine Dugast; Brigitte Gilbert-Dussardier; Olivier Ingster; Pierre Vabres; Frederic Caux; Aurelien de Reynies; Richard Iggo; Nicolas Sevenet; Françoise Bonnet; Michel Longy
Journal:  Breast Cancer Res       Date:  2010-08-16       Impact factor: 6.466

9.  Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation.

Authors:  Laurent Léotoing; Michèle Manin; Didier Monté; Silvère Baron; Yves Communal; Corinne Lours; Georges Veyssière; Laurent Morel; Claude Beaudoin
Journal:  J Mol Endocrinol       Date:  2007-08       Impact factor: 5.098

10.  Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family.

Authors:  Sandeep Sanga; Bradley M Broom; Vittorio Cristini; Mary E Edgerton
Journal:  BMC Med Genomics       Date:  2009-09-11       Impact factor: 3.063

View more
  42 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies.

Authors:  Semir Vranic; Zoran Gatalica; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-11       Impact factor: 2.967

Review 3.  Targeting the androgen receptor in breast cancer.

Authors:  KeeMing Chia; Megan O'Brien; Myles Brown; Elgene Lim
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

4.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

5.  Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study.

Authors:  Ya-Xuan Liu; Ke-Jing Zhang; Li-Li Tang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

6.  ErbB-2 signaling in advanced prostate cancer progression and potential therapy

Authors:  Dannah R Miller; Matthew A Ingersoll; Ming-Fong Lin
Journal:  Endocr Relat Cancer       Date:  2019-04-01       Impact factor: 5.678

7.  Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.

Authors:  Elgene Lim; Min Ni; Shiliang Cao; Aditi Hazra; Rulla M Tamimi; Myles Brown
Journal:  Curr Breast Cancer Rep       Date:  2014-06-01

8.  Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation.

Authors:  Sanjeev K Baniwal; Gillian H Little; Nyam-Osor Chimge; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

Review 9.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28

10.  Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.

Authors:  Lin Zhao; Fengting Niu; Honghong Shen; Xiaozhen Liu; Lijuan Chen; Yun Niu
Journal:  Virchows Arch       Date:  2016-03-30       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.